The administration monitoring cycle of Samsca is changed

Expected to take effect on August 1 after checking opinions

The administration monitoring cycle of Samsca (Tolvaptan) is changed in more detail.

 

Psoriasis arthritis treatment Ixekizumab, which have been used as secondary drugs, and Secukinumab such as Cosentyx will be expanded to primary biological treatments.

 

The MOHW announced on the 20th a partial revision of the "Details on the Standards and Methods of Medical Benefits," which is based on this information, and began to inquire opinions by the 27th.

 

The new drug standards will be applied as of August 1.

 

◆Samsca, a treatment for upper chromosomal polycystic kidney disease, changes the monitoring cycle for administration by reflecting the permission.

 

The MOHW and the HIRA decided to change the monitoring cycle of ADPKD patients and electrolyte levels in consideration of domestic and foreign permits, textbooks, clinical care guidelines, and related academic opinions.

 

Specifically, monitoring, which was conducted once a month before and after the initial administration of this drug, is changed to monthly for the first 18 months before and after the initial administration, and every three months after that.

 

◆Cosentyx and Taltz Prefilled Syringe = Taltz Prefilled Syringe and Cosentyx, which can be used as secondary treatment drugs for psoriasis arthritis, are expanded to primary biological treatments and cautions regarding the risk of tuberculosis infection of biological agents are specified.

 

These drugs will be expanded to the DMARDs non-compliance activities and primary biological sanctions by referring to domestic and foreign permits, textbooks, clinical care guidelines, clinical research documents, and related academic opinions.

 

It was added to implement the late tuberculosis test in the same way as the TNF- in inhibitor, reflecting precautions for use and expert opinions regarding the risk of tuberculosis infection in biological agents.

 

Based on the conditions under administration, the benefits can be applied if two or more types of DMARDs have been treated for more than six months (each three months), or if they meet the conditions as active and progressive arthritis patients who have discontinued treatment due to side effects of drugs.

 

There shall be at least three compressed joints and at least three edema joints, and shall be the result of two consecutive measurements at intervals of one month.

 

The treatment guidelines for late tuberculosis should be followed when using the TNF- in inhibitor.

 

The MOHW plans to inquire about the revision by the 27th and implement it as of August 1st if there is nothing special.